Singapore, June 23 -- Novogene, a global leader in next-generation sequencing (NGS) and multi-omics solutions, has announced the establishment of Novogene Korea Limited, a wholly owned subsidiary headquartered in Seoul.

This strategic expansion deepens Novogene's long-standing engagement with Korea's biomedical and biotech sectors, reinforcing its commitment to delivering rapid, high-quality, and cost-effective multi-omics services tailored to local research needs.

The new entity provides localised customer support, shorter project timelines, and stronger collaboration with Korea's vibrant scientific community - spanning cancer genomics, microbiome studies, precision medicine, and agricultural genomics. Novogene empowers researchers to ...